Clinical study on Lingbao Huxin Pill in treatment of stable coronary artery disease
Objective To explore the efficacy and safety of Lingbao Huxin Pill in the treatment of stable coronary artery disease.Methods A total of 80 patients who visited the Department of Cardiology Outpatient Clinic of Beijing University of Chinese Medicine Third Affiliated Hospital from October 2022 to September 2023 were randomly divided into control group and experimental group.The control group received conventional western medicine treatment,while the experimental group received Lingbao Huxin Pill in addition to the control group.Both groups were treated for four weeks,and the improvement of angina symptoms,nitroglycerin reduction rate,Seattle Scale score,traditional Chinese medicine(TCM)syndrome score,and safety indicators were compared between the two groups.Results A total of 77 patients were finally included in the analysis,including 39 patients in texperimental group and 38 patients in the control group.The baseline data of the two groups were similar and comparable.After four weeks of treatment,the effective rate of angina in experimental group was 89.74％,which was significantly higher than that in control group(57.89％)(P＜0.01),and the nitroglycerin reduction rate in experimental group was 87.18％,which was significantly higher than that in control group(50.00％)(P＜0.01).After treatment,both groups showed significant improvement in Seattle Scale and TCM syndrome scores compared with those before treatment(P＜0.05),and the improvement of Seattle Scale and total TCM syndrome score in experimental group was better than that in control group(P＜0.05).There was no difference in safety indicators between the two groups.Conclusion Lingbao Huxin Pill assisted with conventional western medicine treatment can effectively enhance the clinical efficacy of stable coronary artery disease,and is safe and worthy of clinical promotion.
Lingbao Huxin Pillstable coronary artery diseaseqi deficiency and blood stasis syndromeangina pectorisquality of life
NETL
NSTL
万方数据
